Baird analyst Colleen Kusy lowered the firm’s price target on Coherus Biosciences (CHRS) to $4 from $8 and keeps an Outperform rating on the shares. The firm said Coherus reported 3Q24 results, including higher-than-expected Udenyca revenue despite a temporary supply chain disruption, Loqtorzi sales in line with consensus, and updates for their main clinical assets, casdozo and CHS-114.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS: